ANIXA BIOSCIENCES, INC.: 10-Q filed 2023-03-17

Name: ANIXA BIOSCIENCES, INC.: 10-Q filed 2023-03-17
Creator: ANIXA BIOSCIENCES, INC.

What ANIXA BIOSCIENCES, INC. reported in its quarterly report filed 2023-03-17 (fiscal Q1 2023): 27 published measures, 54 facts as tagged in accession 0001493152-23-007994.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-03-17
Fiscal period: fiscal Q1 2023
Accession: 0001493152-23-007994 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ANIXA BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-01-31	28,306,000	USD
At 2022-10-31	30,412,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-01-31	1,394,000	USD
At 2022-10-31	2,212,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2023-01-31	27,791,000	USD
At 2022-10-31	29,047,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-01-31	9,790,000	USD
At 2022-10-31	12,360,000	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	-2,322,000	USD	92
2021-11-01 to 2022-01-31	-3,829,000	USD	92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	-1,988,000	USD	92
2021-11-01 to 2022-01-31	-1,197,000	USD	92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	3,000	USD	92

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	-585,000	USD	92
2021-11-01 to 2022-01-31	1,850,000	USD	92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-01-31	-220,707,000	USD
At 2022-10-31	-218,385,000	USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	30,921	shares	92
2021-11-01 to 2022-01-31	30,125	shares	92

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	-0.08	USD/shares	92
2021-11-01 to 2022-01-31	-0.13	USD/shares	92

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	957,000	USD	92
2021-11-01 to 2022-01-31	2,135,000	USD	92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	-2,556,000	USD	92
2021-11-01 to 2022-01-31	-3,880,000	USD	92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-01-31	28,105,000	USD
At 2022-10-31	30,200,000	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-01-31	1,232,000	USD
At 2022-10-31	2,037,000	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-01-31	110,000	USD
At 2022-10-31	265,000	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	1,068,000	USD	92
2021-11-01 to 2022-01-31	1,838,000	USD	92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-01-31	30,922,830	shares
At 2022-10-31	30,913,902	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-01-31	248,189,000	USD
At 2022-10-31	247,123,000	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2023-01-31	26,912,000	USD
At 2022-10-31	28,200,000	USD
At 2022-01-31	33,242,000	USD
At 2021-10-31	34,767,000	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2023-01-31	201,000	USD
At 2022-10-31	212,000	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2023-01-31	209,000	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2023-01-31	1,075,000	USD
At 2022-10-31	1,726,000	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-01-31	256,000	USD
At 2022-10-31	466,000	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	-2,354,000	USD	92
2021-11-01 to 2022-01-31	-3,879,000	USD	92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	1,488,000	USD	92
2021-11-01 to 2022-01-31	2,042,000	USD	92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2022-11-01 to 2023-01-31	-155,000	USD	92
2021-11-01 to 2022-01-31	368,000	USD	92

Inspect the source

Entity: ANIXA BIOSCIENCES, INC. / CIK 0000715446
Captured: 2026-09-19T14:58:55.093Z
SEC response SHA-256: e81922dde8f95b9a18ad34411c18fef0305fc9d48fc76607e8e3e2758178634a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000715446.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))